Anavex Life Sciences Corp (AVXL)

Currency in USD
10.970
+0.080(+0.73%)
Closed·
After Hours
10.900-0.070(-0.64%)
·
AVXL Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 5 days
AVXL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
10.52010.990
52 wk Range
4.93014.441
Key Statistics
Prev. Close
10.89
Open
10.71
Day's Range
10.52-10.99
52 wk Range
4.93-14.441
Volume
488.4K
Average Volume (3m)
1.02M
1-Year Change
68.84%
Book Value / Share
1.17
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AVXL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
34.333
Upside
+212.97%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Anavex Life Sciences Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Anavex Life Sciences Corp Company Profile

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company’s ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against the Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.

Anavex Life Sciences Corp Earnings Call Summary for Q1/2025

  • Q4 2024 net loss of $12.1M ($0.14/share); stock rose 3.74% to $8.60 in premarket trading
  • Strong cash position of $120.8M, no debt; cash runway of ~4 years
  • Alzheimer's drug blarcamesine showed 36.3% slowdown in disease progression over 48 weeks
  • CEO highlighted growing stakeholder support for novel precision medicine approach in Alzheimer's
  • Challenges include regulatory hurdles, competition, and gaining market acceptance for new treatment
Last Updated: 12/02/2025, 15:14
Read Full Transcript

Compare AVXL to Peers and Sector

Metrics to compare
AVXL
Peers
Sector
Relationship
P/E Ratio
−19.9x−3.7x−0.5x
PEG Ratio
1.63−0.010.00
Price/Book
9.4x2.3x2.6x
Price / LTM Sales
-10.0x3.3x
Upside (Analyst Target)
285.7%183.7%42.8%
Fair Value Upside
Unlock0.5%6.5%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 34.333
(+212.97% Upside)

Earnings

Latest Release
May 13, 2025
EPS / Forecast
-0.13 / -0.15
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

AVXL Income Statement

People Also Watch

263.10
AVAV
-0.62%
7.900
AMPX
-5.05%
17.580
QBTS
-3.93%
67.46
MP
-1.36%
51.750
ASTS
-1.56%

FAQ

What Stock Exchange Does Anavex Life Sciences Trade On?

Anavex Life Sciences is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Anavex Life Sciences?

The stock symbol for Anavex Life Sciences is "AVXL."

What Is the Anavex Life Sciences Market Cap?

As of today, Anavex Life Sciences market cap is 933.60M.

What Is Anavex Life Sciences's Earnings Per Share (TTM)?

The Anavex Life Sciences EPS (TTM) is -0.56.

When Is the Next Anavex Life Sciences Earnings Date?

Anavex Life Sciences will release its next earnings report on 11 Aug 2025.

From a Technical Analysis Perspective, Is AVXL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Anavex Life Sciences Stock Split?

Anavex Life Sciences has split 2 times.

How Many Employees Does Anavex Life Sciences Have?

Anavex Life Sciences has 42 employees.

What is the current trading status of Anavex Life Sciences (AVXL)?

As of 06 Aug 2025, Anavex Life Sciences (AVXL) is trading at a price of 10.97, with a previous close of 10.89. The stock has fluctuated within a day range of 10.52 to 10.99, while its 52-week range spans from 4.93 to 14.44.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.